Mohs micrographic surgery: a treatment method for many non-melanocytic skin cancers

Dokic, Yelena; Nguyen, Quynh-Giao; Orengo, Ida

doi:10.5070/d3264048344

Cited by 5 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La CMM se convirtió en el estándar de atención para el tratamiento del CPNM de alto riesgo 8 . Por ello, presentamos una cohorte ambispectiva que nos permitió evaluar los resultados estéticos y funcionales de la CMM en el CPNM, utilizando la escala de satisfacción FACE-Q como parámetro evaluador de calidad de vida y cicatrización.…”

Section: Discussionunclassified

Resultados estéticos y funcionales de la cirugía micrográfica de Mohs en cáncer de piel no melanoma

Olmos-Pérez,

Gómez-Angulo,

Rojas-Angarita

et al. 2024

MCUT

View full text Add to dashboard Cite

Antecedentes: El cáncer de piel no melanoma (CPNM) es la neoplasia más frecuente del ser humano. La cirugía micrográfica de Mohs (CMM) es el tratamiento de elección para el CPNM de alto riesgo, permitiendo la eliminación del tumor con mejores resultados oncológicos, estéticos y funcionales. Objetivo: Describir los resultados estéticos y funcionales de la CMM en pacientes con diagnóstico de carcinoma basocelular y carcinoma escamocelular, utilizando la escala de satisfacción FACE-Q. Material y métodos: Estudio de cohorte ambispectiva realizado en tres centros dermatológicos de Bogotá, Colombia, en pacientes que fueron manejados con CMM desde 2012 hasta 2019. Los pacientes completaron el módulo de cáncer de piel de la escala de satisfacción FACE-Q desde junio hasta agosto de 2021 mediante contacto telefónico. Resultados: Se incluyeron 530 pacientes con 650 tumores. El 93.2% de los pacientes completaron la escala FACE-Q. El 92% presentaron adecuada cicatrización en el primer año de seguimiento, con bajos porcentajes de alteraciones en los resultados funcionales. La encuesta FACE-Q se realizó una mediana de 40 meses posterior a la cirugía, con una satisfacción media del 93.2%. Conclusiones: La CMM genera excelentes resultados funcionales y estéticos en los pacientes con CPNM, demostrado por los altos índices de satisfacción evidenciados en la escala FACE-Q por los pacientes.

show abstract

Section: Discussionunclassified

Resultados estéticos y funcionales de la cirugía micrográfica de Mohs en cáncer de piel no melanoma

Olmos-Pérez,

Gómez-Angulo,

Rojas-Angarita

et al. 2024

MCUT

View full text Add to dashboard Cite

show abstract

“…Of note, studies have shown that patients with very small tumors without negative prognostic factors still benefit from radiotherapy [21,22]. The surgical approach for treatment of MCC has not been established yet, but current surgical resection styles are wide local excision (WLE) or Mohs micrographic surgery (MMS) [23,24]. Singh et al compared two groups of MCC patients in a multivariate analysis; one group underwent WLE while the other underwent MMS resection [19].…”

Section: Surgical Treatmentmentioning

confidence: 99%

Updates on the diagnosis, current and future therapeutic options in Merkel-cell carcinoma

2021

View full text Add to dashboard Cite

Merkel-cell carcinoma (MCC) is a rare and extremely aggressive nonmelanocytic cutaneous neuroendocrine carcinoma. Historically, it has been associated with limited therapy options and poor prognosis. While its incidence has been rising over the last two decades, recent discoveries and a better understanding of its pathogenesis, viral association and immunologic features have allowed for the emergence of new therapies. Surgical excision with or without radiotherapy remains the first-line therapy for primary lesions without evidence of metastatic disease. The majority of MCC cases are regrettably diagnosed at advanced stages and oftentimes require systemic therapy. There have been several significant advances in the treatment of MCC in the last decade. Among these have been the development of immune checkpoint inhibitors targeting the programmed death protein-1 (PD-1)/programmed death ligand-1 (PDL-1). Despite recent success of immunotherapy, nearly 50% of patients diagnosed with MCC still succumb to the disease. Fortunately, there has been a number of new targeted therapies that hold great promise. Among them are phosphatidylinositide-3kinase (Pl3K) inhibitors, adoptive T-cell immunotherapy, activated NK-92 cells infusions and therapeutic vaccines. Additional emerging therapeutic targets include cellular ubiquitin-specific processing protease 7 (Usp7) that restricts viral replication and IFN genes (STING), activation of which promotes an antitumor inflammatory response.

show abstract

“…For example, elderly patients are at increased risk for skin cancer [ 3 ], which may require advanced reconstruction with Mohs micrographic surgery [ 34 ]. One in four non-melanoma skin cancers are treated with Mohs micrographic surgery [ 35 ], including dermatofibrosarcoma protuberans, atypical fibroxanthomas, extramammary Paget disease, Merkel cell carcinoma, microcystic adnexal carcinoma, sebaceous carcinoma [ 36 ] and basal cell carcinoma, which represents 80% of all skin cancers [ 37 ]. However, Mohs micrographic surgery carries limitations both functionally and cosmetically, including suboptimal scarring and tissue necrosis.…”

Section: Introductionmentioning

confidence: 99%

3D bioprinting—a model for skin aging

Ansaf

Ziebart

Gudapati

et al. 2023

Regenerative Biomaterials

View full text Add to dashboard Cite

Human lifespan continues to extend as an unprecedented number of people reach their seventh and eighth decade of life, unveiling chronic conditions that affect the older adult. Such skin conditions include senile purpura, seborrheic keratoses, pemphigus vulgaris, bullous pemphigoid, diabetic foot wounds, and skin cancer. Current methods of drug testing prior to clinical trials require the use of pre-clinical animal models, which are often unable to adequately replicate human skin response. A reliable model for aged human skin is needed. Current challenges in developing an aged human skin model include the intrinsic variability in skin architecture from person-to-person. An ideal skin model would incorporate innate functionality such as sensation, vascularization, and regeneration. The advent of 3D bioprinting allows us to create human skin equivalent for use as clinical-grade surgical graft, for drug testing, and other needs. In this review, we describe the process of human skin aging and outline the steps to create an aged skin model with 3D bioprinting using skin cells (i.e., keratinocytes, fibroblasts, and melanocytes). We also provide an overview of current bioprinted skin models, associated limitations, and direction for future research.

show abstract

Mohs micrographic surgery: a treatment method for many non-melanocytic skin cancers

Cited by 5 publications

References 7 publications

Resultados estéticos y funcionales de la cirugía micrográfica de Mohs en cáncer de piel no melanoma

Resultados estéticos y funcionales de la cirugía micrográfica de Mohs en cáncer de piel no melanoma

Updates on the diagnosis, current and future therapeutic options in Merkel-cell carcinoma

3D bioprinting—a model for skin aging

Contact Info

Product

Resources

About